As reported in NASDAQ, Merck Group (German Merck) and Pfizer (NYSE: PFE) announced they would terminate the JAVELINE Ovarian 100 study of avelumab as it did not support the study’s initial hypothesis based on existing trial data. This alliance was the first to test an immunotherapy in this indication, given the significant unmet need in the treatment of ovarian cancer according to NASDAQ.
The topline results showed that the study, which was evaluating avelumab in combination with and/or following platinum-based chemotherapy in previously untreated patients with ovarian cancer, would not achieve superiority in the pre-specified primary endpoint of progression-free survival. The safety profile for avelumab in the trial was consistent with that observed in the overall JAVELIN clinical development program. Four out of five women with ovarian cancer are diagnosed at advanced states. The death rate of advanced ovarian stage cancer is high.